Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Sasanlimab Plus BCG Emerges as a Potential Option for High-Risk NMIBC Despite Predictive Challenges

August 20th 2025

Thomas Powles, MD, MBBS, MRCP, discusses challenges in identifying a predictive biomarker of response for sasanlimab in high-risk, BCG-naive NMIBC.

Dr Wang on Reducing Treatment Discontinuation in Older Patients With mCRPC

August 19th 2025

Jue Wang, MD, discusses the challenge of treatment discontinuation in older patients with metastatic castration-resistant prostate cancer.

Frontline Maintenance Avelumab Plus Sacituzumab Govitecan Extends PFS in Urothelial Cancer

August 19th 2025

JAVELIN Bladder Medley data show PFS improvement with avelumab plus sacituzumab govitecan as first-line maintenance vs avelumab alone in urothelial cancer.

Adjuvant Atezolizumab Boosts DFS, OS in MIBC After Positive MRD Test

August 18th 2025

Adjuvant atezolizumab improved DFS and OS after a positive Signatera MRD test in muscle-invasive bladder cancer.

The OncFive: Top Oncology Articles for the Week of 8/10

August 16th 2025

Vepdegestrant NDA under FDA review in ESR1-mutated breast cancer, Oncomine Dx Target Test gets greenlit as zongertinib companion diagnostic in NSCLC.

Dr Bedke on the Safety Profile of Enfortumab Vedotin/Pembrolizumab in Previously Untreated Advanced Urothelial Carcinoma

August 13th 2025

Jens Bedke, MD, discusses the safety of enfortumab vedotin and pembrolizumab in previously untreated locally advanced or metastatic urothelial carcinoma.

Perioperative Enfortumab Vedotin Plus Pembrolizumab Displays Positive Top-Line Data in Muscle-Invasive Bladder Cancer

August 12th 2025

Perioperative enfortumab vedotin plus pembrolizumab significantly extended survival vs surgery alone in MIBC.

Dr Bedke on Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma

August 8th 2025

Jens Bedke, MD, discusses findings from subgroup analyses of the phase 3 EV-302/KEYNOTE-A39 trial in untreated metastatic urothelial cancer.

NMPA Accepts sNDA for Frontline Toripalimab Plus Disitamab Vedotin in HER2+ Urothelial Carcinoma

August 8th 2025

China’s NMPA has accepted the sNDA for first-line toripalimab plus disitamab vedotin in HER2-expressing locally advanced or metastatic urothelial carcinoma.

Immunotherapy-Based Trials Challenge Chemotherapy Dominance in MIBC

August 5th 2025

Waddah Arafat, MD, discusses the future clinical implications of the ongoing KEYNOTE-B15/EV-304 trial and the safety profile of the NIAGARA trial regimen.

Intravesical Mitomycin Demonstrates 24-Month Durability in Recurrent Low-Grade, Intermediate-Risk NMIBC

August 5th 2025

Intravesical mitomycin produced a 24-month DOR rate of 72.2% in recurrent low-grade, intermediate-risk NMIBC.

NIAGARA Data Raise Questions About the Role of MVAC in Resectable MIBC

August 4th 2025

Waddah Arafat, MD, discusses the treatment paradigm for MIBC and questions regarding the benefit seen with neoadjuvant chemoimmunotherapy in this setting.

TAR‑200 Could Alter Nonsurgical Management of BCG‑Unresponsive NMIBC

August 1st 2025

Joseph Jacob, MD, MCR, discusses how TAR‑200 could represent a new treatment avenue in BCG‑unresponsive, high-risk NMIBC.

Dr Sonpavde on OS Data With Ipilimumab/Nivolumab in Previously Untreated, Advanced Urothelial Carcinoma

July 31st 2025

Guru P. Sonpavde, MD, details overall survival data with ipilimumab/nivolumab vs gemcitabine/platinum in previously untreated, advanced urothelial cancer.

Dr Hayne on the Rationale for Evaluating Mitomycin Plus BCG vs BCG Alone in NMIBC

July 31st 2025

Dickon Hayne, MD, FRCS, MBBS, discusses the rationale for evaluating the addition of mitomycin to BCG in non–muscle-invasive bladder cancer.

Biomarkers May Inform Potential Role for Ipilimumab/Nivolumab in Untreated Metastatic Urothelial Cancer After Missing OS End Point

July 30th 2025

Guru P. Sonpavde, MD, discusses the role of ipilimumab/nivolumab after negative trial results in managing advanced urothelial cancer.

Five Under 5: Top Oncology Videos for the Week of 7/13

July 20th 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

FDA Grants Priority Review to TAR-200 for BCG-Unresponsive High-Risk NMIBC

July 17th 2025

The FDA has granted priority review to TAR-200 for BCG-unresponsive, high-risk NMIBC with CIS, with or without papillary tumors.

Five Under 5: Top Oncology Videos for the Week of 7/6

July 13th 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

Dr Hayne on the Implications of the ANZUP 1301 Trial of Mitomycin Plus BCG in NMIBC

July 9th 2025

Dickon Hayne, MD, FRCS, MBBS, discusses mitomycin in combination with BCG in patients with high-risk non–muscle-invasive bladder cancer.